



Balfour Capital Group Hologic, Inc.

Hologic is a women's-health-focused med-tech company with three core franchises: Diagnostics (molecular/Pap/sexually transmitted infection assays, Panther systems), Breast Health (3D mammography/tomosynthesis, biopsy), and GYN Surgical (MyoSure, NovaSure).

1. Top 5 Competitors

- GE HealthCare – breast imaging/tomosynthesis.
- Siemens Healthineers – breast imaging/IVD.
- Fujifilm – mammography.
- BD (Becton Dickinson) – women's health & molecular diagnostics/collection devices.
- Roche Diagnostics (alt: Abbott) – women's health & broader IVD.

2. Largest Institutional Shareholders

- Vanguard Group; BlackRock
- T. Rowe Price Investment Mgmt
- Morgan Stanley
- State Street.

3. Management Team

- Stephen P. MacMillan – Chairman, President & CEO
- Essex Mitchell – Chief Operating Officer
- Karleen Oberton – Chief Financial Officer
- Jan Verstreken – Group President, International
- (plus other segment leaders/VPs)



Balfour Capital Group Hologic, Inc.

4. Revenue

- FY2024 revenue: \$4.03B (vs. \$4.03B FY2023).
- Q3 FY2025 revenue: \$1.024B (+1.2% y/y).

5. Institutions with Buy Recommendations:

- Citi (upgrade to Buy, Jul 2025)
- Mizuho (Outperform)
- UBS (Buy)
- Barclays (Overweight)
- Stifel (Buy)
- Morgan Stanley (Overweight).

6. Analyst Sentiment Summary

Recent tally shows a Hold / Moderate Buy skew overall. WSJ shows roughly 6 Buy, 2 Overweight, 15 Hold, 1 Underweight with ~\$70 avg PT; MarketBeat/others characterize it as Moderate Buy.

7. Insider Buying and Selling (Last 24 Months)

- Buying: Limited. MarketBeat logs ~5,445 shares bought (~\$301K), primarily by director Martin D. Madaus.
- Selling: Ongoing programmatic sales by executives (e.g., CEO Stephen MacMillan and others via Form 4s).
- Public trackers (Nasdaq/Yahoo/TipRanks) reflect far more selling than buying over the period.